CRISPR Therapeutics is a pioneering biotech firm leveraging CRISPR gene editing to create curative treatments for rare genetic diseases with significant commercial potential.
The potential for CRISPR Therapeutics to deliver a curative treatment for sickle cell disease represents a massive one-time revenue opportunity that could transform its financial trajectory in the coming years. Strong cash reserves and strategic partnerships provide sufficient runway to continue advancing its pipeline without immediate need for dilutive capital raises.
The company's recurring losses of over $500 million annually highlight an unsustainable burn rate if clinical success does not materialize quickly enough to generate meaningful commercial revenue. The sharp decline in recent revenue trends suggests significant uncertainty surrounding the timing of regulatory approvals and commercial launch dates for its pipeline products.
CRISPR Therapeutics AG is a global leader in CRISPR-based gene editing technologies, focusing on developing first-in-class therapies for serious genetic diseases such as sickle cell disease. The company serves markets across North America, Europe, and Asia through its proprietary platform designed to treat conditions like beta-thalassemia, transthyretin amyloidosis, and cholesterol disorders.
Despite a significant net loss of $581.6 million in the latest period, the company successfully navigated high R&D expenditures of $284.8 million while maintaining a healthy cash position exceeding $347 million. Revenue growth has been volatile, dropping sharply from $371.2 million in 2023 to $3.5 million recently, likely reflecting the transition phase between clinical trials and commercialization timelines.
The gene editing industry is characterized by high barriers to entry due to complex technology requirements and stringent regulatory standards, favoring well-capitalized players like CRISPR Therapeutics. However, the sector remains highly competitive with numerous startups and major pharmaceutical companies investing heavily in developing novel therapies for genetic disorders.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.2M | $371.2M | $37.3M | $3.5M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.2M | $371.2M | $37.3M | $3.5M |
| Operating Expenses | $674.4M | $593.7M | $503.9M | $668.1M |
| Operating Income | $-673.2M | $-222.5M | $-466.6M | $-664.6M |
| R&D | $461.6M | $387.3M | $320.7M | $284.8M |
| G&A | $102.5M | $76.2M | $73.0M | $73.5M |
| Stock-Based Comp | $97.9M | $81.0M | $86.6M | $72.5M |
| D&A | $24.2M | $19.8M | $19.3M | $19.5M |
| Depreciation | $24.1M | $19.8M | $19.2M | $19.4M |
| Other OpEx | $110.2M | $130.2M | $110.2M | $309.7M |
| Non-Operating Income | $22.7M | $71.8M | $103.9M | $86.6M |
| Interest Income | — | — | $104.3M | — |
| Pre-Tax Income | $-650.5M | $-150.7M | $-362.7M | $-578.0M |
| Income Tax | $-325.0K | $2.9M | $3.6M | $3.6M |
| Continuing Ops | $-650.2M | $-153.6M | $-366.3M | $-581.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-650.2M | $-153.6M | $-366.3M | $-581.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-650.2M | $-153.6M | $-366.3M | $-581.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.85B | $1.91B | $1.94B | $1.99B |
| Cash & Equivalents | $211.9M | $389.5M | $298.3M | $347.6M |
| Marketable Securities | $1.60B | $1.30B | $1.61B | $1.63B |
| Accounts Receivable | $0 | $200.0M | $25.0M | $0 |
| Prepaid Expenses | $37.7M | $14.4M | $8.3M | $9.8M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $390.0M | $321.5M | $304.9M | $279.6M |
| PP&E (Net) | $163.6M | $151.9M | $134.1M | $115.9M |
| Operating Leases | $156.9M | $154.0M | $143.5M | $131.7M |
| LT Securities | $53.1M | $2.0M | $0 | $0 |
| Other LT Assets | $16.3M | $13.6M | $27.3M | $32.0M |
| Total Assets | $2.24B | $2.23B | $2.24B | $2.27B |
| Current Liabilities | $121.1M | $108.8M | $87.8M | $149.1M |
| Accounts Payable | $27.4M | $38.1M | $14.7M | $11.1M |
| Current Leases | $15.8M | $15.6M | $17.3M | $18.6M |
| Deferred Revenue | $0 | $4.1M | $3.8M | $15.8M |
| Other Current Liab | $155.0K | $5.6M | $10.9M | $14.2M |
| Long-Term Liabilities | $246.5M | $238.0M | $222.2M | $194.3M |
| LT Operating Leases | $228.2M | $223.0M | $206.4M | $188.2M |
| Other LT Liab | $6.0M | $958.0K | $3.4M | $6.1M |
| Total Liabilities | $367.6M | $346.8M | $310.0M | $343.4M |
| Shareholders' Equity | $1.88B | $1.88B | $1.93B | $1.92B |
| Retained Earnings | $-846.1M | $-999.7M | $-1.37B | $-1.95B |
| AOCI | $-15.6M | $1.9M | $1.8M | $4.8M |
| Treasury Stock | $63.0K | $62.0K | $62.0K | $60.0K |
| Total L&E | $2.24B | $2.23B | $2.24B | $2.27B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-650.2M | $-153.6M | $-366.3M | $-581.6M |
| Non-Cash Adjustments | $153.7M | $-269.2M | $423.4M | $216.2M |
| Working Capital Changes | $729.0K | $162.4M | $-199.9M | $20.4M |
| Cash from Operations | $-495.7M | $-260.4M | $-142.8M | $-345.0M |
| Capital Expenditures | $37.2M | $9.5M | $1.9M | $914.0K |
| Cash from Investing | $-258.7M | $374.6M | $-280.5M | $-31.8M |
| Cash from Financing | $38.6M | $62.7M | $332.0M | $426.0M |
| FX Effect | $-80.0K | $73.0K | $-21.0K | $95.0K |
| Net Change in Cash | $-715.9M | $177.0M | $-91.3M | $49.3M |
| Beginning Cash | $939.9M | $224.1M | $401.1M | $309.8M |
| Ending Cash | $224.1M | $401.1M | $309.8M | $359.1M |
The company's revenue streams are primarily driven by licensing agreements and upfront payments from major pharmaceutical partners, as well as milestone payments contingent upon the successful development of specific therapies like CTX001. A smaller portion of revenue comes from product sales or royalties generated by its approved gene-editing medicines entering the commercial market.
Investors must consider the high risk of clinical trial failures which could result in substantial write-downs or loss of future milestone payments. Regulatory hurdles for gene therapies can be unpredictable and costly, potentially delaying market entry or requiring expensive post-market surveillance programs. The company faces intense competition from other biotech firms developing similar gene editing technologies, which could erode its market share.
CRISPR Therapeutics possesses a deep intellectual property portfolio that provides exclusive rights to CRISPR technology for therapeutic applications in humans, creating a robust defensive moat against competitors. The company benefits from strong validation through partnerships with top-tier biopharma firms like Vertex Pharmaceuticals and Verve Therapeutics, ensuring a steady pipeline of development assets.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.